IDE requested for "self-growing" heart valve:
This article was originally published in Clinica
CryoLife has submitted an investigational device exemption (IDE) application to the FDA to begin US trials of its SynerGraft tissue-engineered pulmonary heart valve, intended for children. The product is a collagen frame based on a porcine valve from which the cells have been removed. Animal studies show that the frame is re-populated by the recipient's own cells and grows as the recipient grows. Six Australian adults already have SynerGraft implants and all are "doing well", says the Atlanta, Georgia-based company. It hopes the US trials will recruit up to 150 pediatric patients. Meanwhile European regulators are considering the product for CE-marking, the company claims.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.